Oseltamivir Dosing in ESRD on Hemodialysis
For patients with end‑stage renal disease on hemodialysis, administer oseltamivir 30 mg immediately after every hemodialysis session for treatment (not to exceed 5 days total) or after every other hemodialysis session for prophylaxis. 1
Treatment Regimen (Acute Influenza)
- Dose: 30 mg orally after each hemodialysis session 1
- Duration: Continue for up to 5 days total (typically 3–4 doses if dialyzing three times weekly) 1
- Timing: Administer immediately after completing the dialysis session 1
- First dose consideration: If influenza is diagnosed between dialysis sessions, give 30 mg immediately without waiting for the next session—this rapidly raises oseltamivir carboxylate concentrations without safety risk 2
Prophylaxis Regimen (Post‑Exposure or Seasonal)
- Dose: 30 mg orally after every other hemodialysis session 1
- Duration: At least 10 days for post‑exposure prophylaxis; up to 6 weeks (or 12 weeks in immunocompromised patients) for seasonal prophylaxis 1
- Timing: Administer immediately after completing the dialysis session 1
Rationale for Dosing
- Oseltamivir carboxylate (the active metabolite) is cleared 7.43 liters/minute during hemodialysis versus only 0.19 liter/minute between sessions, making dialysis the dominant route of elimination 2
- The 30 mg post‑dialysis regimen produces trough concentrations above the median achieved with standard 75 mg twice‑daily dosing in patients with normal renal function, while keeping peak concentrations well below toxic thresholds 2
- A single‑dose pharmacokinetic study in hemodialysis patients demonstrated that 30 mg after alternate sessions provides adequate oseltamivir carboxylate exposure (AUC₀₋₄₂ = 31,600–38,200 ng·h/mL) for both treatment and prophylaxis 3
Formulation and Administration
- Use the oral suspension (6 mg/mL) for the 30 mg dose, which equals 5 mL 1
- Alternatively, open a 30 mg capsule if suspension is unavailable 4
- Administer with food to reduce nausea and vomiting, which occur in approximately 10% of patients 4, 5
Critical Pitfalls to Avoid
- Do not use the 75 mg once‑daily regimen recommended for creatinine clearance 10–30 mL/min; hemodialysis patients require the lower 30 mg dose because dialysis removes the drug efficiently 1
- Do not dose on non‑dialysis days for treatment (only prophylaxis uses every‑other‑session dosing) 1
- Do not wait for the next scheduled dialysis session if influenza is diagnosed mid‑cycle—give 30 mg immediately to achieve therapeutic concentrations early 2
- Do not use oseltamivir in ESRD patients not on dialysis—the drug is not recommended in this population due to excessive accumulation 1
Special Considerations
- Timing of therapy: Initiate treatment within 48 hours of symptom onset for maximal benefit; earlier initiation (within 12–24 hours) yields the greatest reduction in illness duration 4, 5
- Safety profile: Oseltamivir was well tolerated in hemodialysis patients at the 30 mg dose, with no dose‑limiting toxicity observed 3, 2
- Continuous ambulatory peritoneal dialysis (CAPD): If the patient is on CAPD instead of hemodialysis, give a single 30 mg dose immediately for treatment, or 30 mg immediately followed by 30 mg once weekly for prophylaxis 1